International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 5, Issue 11 | Case Report | Open Access
Tessy María López Goerne*
1Department of Health Care, Autonomous Metropolitan University—Xochimilco, Mexico City, Mexico
2Department of Nanotechnology, School of Science and Engineering, Tulane University, New Orleans, Louisiana, USA
*Correspondence to: Tessy María López Goerne
Fulltext PDFThis paper presents the clinical case of a patient with glioblastoma (GB)—the most extensively studied tumor in research laboratories because of its high malignancy and its unique ability to sustain itself by taking up nutrients, effectively granting it a "life of its own." Although the tumor is surgically removed and treated with radiotherapy and chemotherapy, it typically regrows rapidly by drawing sustenance from the cerebrospinal fluid (CSF). It actively recruits a wide array of substances, including lipids, lipid droplets, carbohydrates, peptides, and even genetic material. Furthermore, the tumor exhibits resistance to chemotherapeutic agents such as temozolomide or carboplatin, while these drugs simultaneously cause severe neurological side effects in the patient. In this study, we treat the patient’s GB using a state-of-the-art Pt/TiO2 nanobiocatalyst that enters malignant cells via receptor-mediated endocytosis without affecting healthy cells. The mechanism of action of these nanoparticles is clearly explained. While traditional GB treatments typically yield a survival period of 6 to 12 months, this innovative alternative offers an average survival of 36 months. Various nanoparticles are currently under investigation to combat this type of brain cancer, and all such alternatives represent a significant improvement over conventional chemotherapy.
GB; Ultra-nanoparticles; Pt/TiO2 (1%) bionanocatalyst; Side effects; Survival
Tessy López-Goerne, Dulce Gurgua. Cytotoxic Titania (TiO2) Ultra-nanoparticles Functionalized with 1% Platinum for the Treatment of Glioblastoma. Int Clinc Med Case Rep Jour. 2026;5(11):1-9.